Landmark Trial Tests Whether Chemotherapy Can Be Spared in High-Risk Early Breast Cancer

A major new clinical trial is set to challenge one of the most persistent treatment dilemmas in early-stage breast cancer. The ECOG-ACRIN Cancer Research Group has launched RxFINE-Low, known formally as EA1242, a phase 3 randomized study designed to determine whether patients whose breast tumors carry low-risk biology but high-risk anatomy can safely forgo chemotherapy. The question matters because thousands of patients each year receive adjuvant chemotherapy based on tumor size and lymph node involvement alone, even when genomic testing suggests their cancer may behave less aggressively.

The trial targets a specific subgroup of patients with estrogen receptor-positive, HER2-negative breast cancer, the most common molecular subtype of the disease. In current practice, patients whose tumors exceed five centimeters or who have cancer in more than three lymph nodes are routinely offered chemotherapy, regardless of what their tumor’s genomic profile reveals. This anatomic risk, reflecting the physical burden of disease, has long been treated as an automatic trigger for intensive treatment. RxFINE-Low will test whether tumor biology, measured by a widely used genomic assay, can safely override that convention.

Study chair Nancy Chan, MD, a medical oncologist at New York University’s Perlmutter Cancer Center at NYU Langone, framed the central question of the research. According to Chan, RxFINE-Low seeks to answer a critical question in breast cancer care: can patients with high anatomic risk but low genomic risk do similarly well without chemotherapy? She noted that the trial will assess whether tumor biology, rather than anatomic tumor burden alone, can guide treatment decisions, and whether chemotherapy can be omitted in some patients.

The scientific foundation for this question rests on two landmark studies. The TAILORx and RxPONDER trials, both conducted by ECOG-ACRIN, established that adjuvant chemotherapy is generally not necessary for postmenopausal patients with earlier-stage ER-positive, HER2-negative breast cancer whose tumors score low on the Oncotype DX Breast Recurrence Score and who have involvement in up to three lymph nodes. Those findings transformed clinical practice for a broad population of patients. What they did not answer, however, is whether the same principle extends to patients with larger tumors or more extensive nodal spread. That question has never been evaluated in a large prospective randomized trial, leaving chemotherapy as the standard approach for this group.

A second wave of therapeutic progress has complicated the picture further. The NATALEE and monarchE trials demonstrated that adding a CDK4/6 inhibitor to endocrine therapy reduces the risk of recurrence in high-risk early-stage ER-positive, HER2-negative breast cancer, changing the standard of care. Ribociclib, the CDK4/6 inhibitor used in RxFINE-Low, works by blocking proteins that drive cell division, complementing the hormone-blocking effects of endocrine therapy. Yet most participants in those pivotal studies had already received chemotherapy before enrollment, which means the incremental benefit of chemotherapy itself could not be isolated or evaluated in that modern treatment context.

RxFINE-Low is the first prospective randomized phase 3 trial specifically designed to address this gap. The study will enroll nearly 2,000 postmenopausal women and men whose breast cancer qualifies as high anatomic risk, defined as a tumor larger than five centimeters or cancer in more than three lymph nodes, and whose tumors show low genomic risk on the Oncotype DX assay, indicated by a Breast Recurrence Score between 0 and 25. Because genomic testing has not been prospectively validated in patients with high anatomic risk disease, many insurers do not routinely cover Oncotype DX testing for these patients, a coverage gap the trial’s results could help close.

Participants will be randomized in equal proportions to one of two treatment strategies. The control arm reflects the current standard of care: adjuvant chemotherapy followed by endocrine therapy combined with ribociclib. The experimental arm omits chemotherapy entirely, pairing endocrine therapy with ribociclib alone. The primary endpoint is invasive breast cancer-free survival, a measure of whether patients remain free of invasive disease over time. Participants will be followed for up to ten years, allowing researchers to evaluate recurrence, survival, treatment-related side effects, and other study endpoints across a decade of clinical outcomes.

Beyond its primary endpoint, the trial is built to generate lasting scientific value. Researchers will collect tumor tissue and blood samples from participants to support future translational research, potentially revealing biological markers that could refine treatment selection even further. As Chan observed, treatment options are evolving, and equally rigorous evidence is needed to determine which patients may omit chemotherapy. She emphasized that RxFINE-Low is designed to provide prospective evidence in this space, evidence that could reshape guidelines and clinical decision-making for years to come.

The potential benefits of a negative trial extend well beyond avoiding a few months of intravenous treatment. Chemotherapy carries short-term toxicities including nausea, fatigue, infection risk, and hair loss, as well as long-term risks such as cardiac dysfunction, cognitive effects, and secondary malignancies. If chemotherapy can be safely omitted in patients with low genomic risk, the findings could spare many patients these harms while maintaining the recurrence protection already offered by endocrine therapy and CDK4/6 inhibition. The results could also provide prospective evidence to inform future coverage decisions, since the trial would be the first to validate genomic testing in this high anatomic risk population.

The National Cancer Institute, part of the U.S. National Institutes of Health, is sponsoring the study, which ECOG-ACRIN is conducting through the NCI’s National Clinical Trials Network. Novartis Pharmaceuticals Corporation is providing support through a Cooperative Research and Development Agreement with the NCI. ECOG-ACRIN, one of the world’s leading scientific organizations with more than 1,400 hospitals and cancer centers across the United States and worldwide and nearly 21,000 researchers and advocates, has a track record of practice-changing trials including TAILORx, TMIST, NCI-MATCH, and ComboMATCH. If RxFINE-Low delivers a clear answer, it could mark the next step in a decades-long effort to match breast cancer treatment to the biology of each patient’s tumor rather than the anatomy of its spread.

Subject of Research: A randomized phase 3 trial evaluating whether chemotherapy can be omitted in high anatomic risk, low genomic risk early-stage ER-positive HER2-negative breast cancer treated with endocrine therapy and a CDK4/6 inhibitor.

Article Title: ECOG-ACRIN launches a landmark trial to evaluate chemotherapy benefit in high-risk early-stage breast cancer

Article References: ECOG-ACRIN launches a landmark trial to evaluate chemotherapy benefit in high-risk early-stage breast cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: breast cancer, chemotherapy, CDK4/6 inhibitors, ribociclib, Oncotype DX, endocrine therapy, ECOG-ACRIN, clinical trial, genomic risk, anatomic risk, ER-positive HER2-negative, adjuvant therapy